Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Filed for shelved prospectus of 100M

<< Previous

Bullboard Posts

Next >>

Comment by PWIB123on Dec 21, 2023 4:49pm

91 Views

Post# 35796580

RE:Filed for shelved prospectus of 100M

It's just replacing the one that was already filed and is expiring. THTX has a remarkable ability to have non-important events happen around timing of events that seem important. At this point, they have to prove it before I'll believe any tea leaves.

<< Previous

Bullboard Posts

Next >>

Full Circle Lithium goes global with its battery fire-fighter